新癀片联合复方桐叶烧伤油治疗急性痛风性关节炎患者的疗效分析

doi:10.3760/cma.j.issn.1007-1245.2024.07.019

摘要/Abstract

摘要：

目的　观察新癀片联合复方桐叶烧伤油治疗急性痛风性关节炎的疗效。方法　采用前瞻性干预性研究。选取2022年1月至12月在南昌大学第一附属医院接受治疗的96例急性痛风性关节炎患者作为研究对象，采用随机数字表法将其分为3组，每组32例。A组男28例、女4例，年龄（53.37±16.53）岁，急性病程（2.56±0.92）d，在常规治疗基础上加用新癀片外敷；B组男30例、女2例，年龄（54.18±17.42）岁，急性病程（2.53±0.89）d，在常规治疗基础上加用复方桐叶烧伤油；C组男29例、女3例，年龄（53.61±17.21）岁，急性病程（2.61±0.93）d，在常规治疗基础上采用新癀片+复方桐叶烧伤油外敷，干预周期均为1周。对比3组患者一般资料（年龄、性别、体质指数、饮酒、吸烟及急性病程）、治疗前及治疗后1、3、5、7 d视觉模拟评分法（VAS）评分、治疗前及治疗后1、3、5、7 d骨关节炎指数（WOMAC）、中医证候疗效。统计学方法采用t检验、χ²检验。结果　3组急性痛风性关节炎患者一般资料比较，差异均无统计学意义（均P>0.05）。治疗前及治疗后1 d，3组患者VAS评分比较，差异均无统计学意义（均P>0.05）；治疗后3、5、7 d，3组患者VAS评分比较，差异均有统计学意义（均P<0.05）；C组治疗后3、5、7 d的VAS评分［（4.84±1.30）分、（2.97±1.31）分、（1.81±1.15）分］均低于A组［（5.63±1.26）分、（4.34±1.33）分、（2.97±1.28）分］、B组［（6.38±1.21）分、（5.38±1.21）分、（5.38±1.21）分］，差异均有统计学意义（均P<0.05）。治疗前及治疗后1 d，3组患者WOMAC评分比较，差异均无统计学意义（均P>0.05）；治疗后3、5、7 d，3组患者WOMAC评分比较，差异均有统计学意义（均P<0.05）；C组治疗后3、5、7 d的WOMAC评分［（113.50±28.78）分、（82.66±31.82）分、（50.19±34.90）分］均低于A组［（128.09±25.59）分、（110.31±28.29）分、（87.84±33.19）分］、B组［（154.19±20.59）分、（148.19±20.59）分、（137.28±20.62）分］，差异均有统计学意义（均P<0.05）。C组总有效率为96.9%（27/32），高于A组［78.1%（25/32）］、B组［53.1%（17/32）］，差异有统计学意义（χ²=49.937，P<0.001）。结论　新癀片联合复方桐叶烧伤油治疗急性痛风性关节炎疗效较好，能缩短病程，减轻患者痛苦，同时可降低临床护理人员更换敷料频率。

关键词:

痛风性关节炎, 新癀片, 复方桐叶烧伤油, 肿胀, 疼痛

Abstract:

Objective　To observe the curative effect of Xinhuang tablets combined with Fufang Tongye Shaoshang You for patients with acute gouty arthritis. Methods　A total of 96 patients with acute gouty arthritis treated at First Hospital, Medical College, Nanchang University from January 2022 to December 2022 were selected, and divided into group A, group B, and group C by the random number table method, with 32 cases in each group. There were 28 males and 4 females in group A; they were (53.37±16.53) years old; their acute disease course was (2.56±0.92) d. There were 30 males and 2 females in group B; they were (54.18±17.42) years old; their acute disease course was (2.53±0.89) d. There were 29 males and 3 females in group C; they were (53.61±17.21) years old; their acute disease course was (2.61±0.93) d. The three groups were treated with conventional drugs; in addition, group A were treated with Xinhuang tablets, group B with Fufang Tongye Shaoshang You, and group C with Xinhuang tablets and Fufang Tongye Shaoshang You. All the three groups were observed 3 weeks. The general data (age, gender, body mass index, drinking, smoking, and acute disease course), scores of Visual Analogue Scale (VAS) and osteoarthritis index (WOMAC) before and 1, 3, 5, and 7 d after the treatment, and traditional Chinese medicine syndrome efficacies were compared between the 3 groups. t and χ² tests were applied. Results　There were no statistical differences in the general data between the three groups (all P>0.05). There were no statistical differences in the scores of VAS before and 1 d after the treatment between the three groups (both P>0.05). There were statistical differences in the scores of VAS 3, 5, and 7 d after the treatment between the three groups (all P<0.05). The scores of VAS 3, 5, and 7 d after the treatment in the group C [(4.84±1.30), (2.97±1.31), and (1.81±1.15)] were lower than those in group A [(5.63±1.26), (4.34±1.33), and (2.97±1.28)] and group B [(6.38±1.21), (5.38±1.21), and (5.38±1.21)], with statistical differences (all P<0.05). There were no statistical differences in the scores of WOMAC before and 1 d after the treatment between the three groups (both P>0.05). There were statistical differences in the scores of WOMAC 3, 5, and 7 d after the treatment between the three groups (all P<0.05). The scores of WOMAC 3, 5, and 7 d after the treatment in the group C [(113.50±28.78), (82.66±31.82), and (50.19±34.90)] were lower than those in group A [(128.09±25.59), (110.31±28.29), and (87.84±33.19)] and group B [(154.19±20.59), (148.19±20.59), and (137.28±20.62)], with statistical differences (all P<0.05). The total effective rate in group C was 96.9% (27/32), that in group A 78.1% (25/32), and that in group B 53.1% (17/32), with a statistical difference (χ²=49.937, P<0.001). Conclusion　Xinhuang tablets combined with Fufang Tongye Shaoshang You for patients with acute gouty arthritis is effective, and can shorten their disease course, relieve their pain, and reduce the frequency of dressing replacement by clinical nurses.

Key words:

Gouty arthritis, Xinhuang tablets, Fufang Tongye Shaoshang You, Swelling, Pain

胡伟袁文霞熊文佳刘焕兵.

新癀片联合复方桐叶烧伤油治疗急性痛风性关节炎患者的疗效分析 [J]. 国际医药卫生导报, 2024, 30(7): 1152-1156.

Hu Wei, Yuan Wenxia, Xiong Wenjia, Liu Huanbing.

Effect of Xinhuang tablets combined with Fufang Tongye Shaoshang You for patients with acute gouty arthritis [J]. International Medicine and Health Guidance News, 2024, 30(7): 1152-1156.

参考文献

[1] Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors[J].Nat Rev Rheumatol,2015,11(11):649-662.DOI:10.1038/nrrheum.2015.91.
[2] Roddy E, Choi HK. Epidemiology of gout[J].Rheum Dis Clin North Am,2014,40(2):155-175.DOI:10.1016/j.rdc.2014.01.001.
[3] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志,2016,55(11):892-899.DOI:10.3760/cma.j.issn.0578-1426.2016.11.019.
[4] Smith HS, Bracken D, Smith JM. Gout: current insights and future perspectives[J].J Pain,2011,12(11):1113-1129.DOI:10.1016/j.jpain.2011.06.009.
[5] Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout[J].Adv Ther,2015,32(1):31-41.DOI:10.1007/s12325-014-0175-z.
[6] 戈颖莹,雷媛,祁舒,等. 新癀片治疗急性痛风性关节炎的成本效果分析[J]. 中国药物评价,2018,35(1):56-61.DOI:10.3969/j.issn.2095-3593.2018.01.018.
[7] 邓金星,张锦友,邓飞扬. 复方桐叶烧伤油联合银离子抗菌功能性敷料治疗大面积烧伤残余创面的疗效观察[J]. 江西医药,2020,55(4):416-417.DOI:10.3969/j.issn.1006-2238. 2020.04.017.
[8] Borman P, Kaygisiz F, Yaman A. Neuropathic component of low back pain in patients with ankylosing spondylitis[J].Mod Rheumatol,2021,31(2):462-467.DOI:10.1080/14397595.2020.1754322.
[9] 王梅生,徐根山,王乐荣. 针刺治疗膝骨性关节炎临床观察[J]. 光明中医,2023,38(16):3173-3175.DOI:10.3969/j.issn.1003-8914.2023.16.030.
[10] 王瑛瑶. 慢湿灵汤联合蝎黄软膏治疗慢性手角化湿疹的临床观察[D].哈尔滨:黑龙江中医药大学,2024.DOI:10.27127/d.cnki.ghlzu.2023.000603.
[11] 廖家鑫,朱钰,王润鹏,等. 刺血疗法治疗急性痛风性关节炎的Meta分析[J]. 中国医学创新,2020,17(35):141-146.DOI:10.3969/j.issn.1674-4985.2020.35.035.
[12] 曹会波,周彩彩,吴杰,等. 四妙散加味内服联合黄药膏外用治疗急性痛风性关节炎的临床效果研究[J]. 中国实用医药,2023,18(20):24-27.DOI:10.14163/j.cnki.11-5547/r.2023.20.006.
[13] 傅汝刚,程志刚,顾春松,等. 苗药痛风灵对湿热痹阻型急性痛风性关节炎疗效及对细胞因子水平的影响[J]. 亚太传统医药,2023,19(12):98-102.DOI:10.11954/ytctyy. 202312018.
[14] 王晓跃,黄伟斌,许冬青,等. 丹溪痛风方联合活血止痛膏治疗不同中医辨证急性痛风性关节炎患者的临床效果[J]. 中国药物经济学,2020,15(5):112-114,121.DOI:10.12010/j.issn.1673-5846.2020.05.026.
[15] Chi X, Zhang H, Zhang S, et al. Chinese herbal medicine for gout: a review of the clinical evidence and pharmacological mechanisms[J].Chin Med,2020,15:17.DOI:10.1186/s13020-020-0297-y.
[16] Xiao YZ, Ye ZZ, Liang YT, et al. Association between Chinese herbal medicine therapy and the risk of chronic kidney disease in gout patients[J].Front Pharmacol,2021,12:661282.DOI:10.3389/fphar.2021.661282.
[17] Pan X, Zhou J, Chen Y, et al. Classification, hepatotoxic mechanisms, and targets of the risk ingredients in traditional Chinese medicine-induced liver injury[J].Toxicol Lett,2020,323:48-56.DOI:10.1016/j.toxlet. 2020.01.026.
[18] 方磊,石汉振,李雅茜,等. 伤柏膏对急性痛风关节炎患者的影响[J]. 国际医药卫生导报,2021,27(16):2525-2529.DOI:10.3760/cma.j.issn.1007-1245.2021.16.024.
[19] 丁志明,张宸玥,王辉. 新癀片治疗带状疱疹有效性和安全性的系统评价[J]. 天津中医药,2023,40(11):1438-1444. DOI:10.11656/j.issn.1672-1519.2023.11.15.
[20] 唐佳,张超,熊维建,等. 100例新癀片联合黄马酊和槐花蜂蜜治疗急性痛风性关节炎临床观察[J].重庆医学,2017,46(24):3404-3405.DOI:10.3969/j.issn.1671-8348. 2017.24.028.
[21] 张京慧. 新癀片外敷治疗痛风性关节炎效果观察[J]. 护理研究,2006,20(29):2668-2669.DOI:10.3969/j.issn.1009- 6493.2006.29.020.
[22] 黎姣. 新癀片外敷治疗慢性痛风性关节炎的效果观察[J]. 全科护理,2013,11(1):16-16.DOI:10.3969/j.issn.1674- 4748. 2013.01.010.
[23] 姚小梅,徐虎军. 自制紫归油联合新癀片在褥疮患者治疗中的应用效果[J]. 医疗装备,2020,33(6):72-73.DOI:10.3969/j.issn.1002-2376.2020.06.047.